The Survivors for Solutions 2025 Patient Policy Roadmap is now available!. Learn more about which policies patients support, like those that mitigate the negative impacts of the IRA to protect innovation, and which they oppose here:.

Middlemen standing between patients and their medications drive up costs and inhibit access. Survivors for Solutions thanks panelists in yesterday's @FTC/@TheJusticeDept listening session for highlighting the practices of shady drug middlemen.

Yesterday's @FTC/@TheJusticeDept listening session on drug pricing highlighted that IP protections are critical to allow for follow-on research that can find additional, potentially life-saving uses for existing medications. Patients desperately awaiting a cure cannot afford any.

Importing socialist drug pricing systems that put the sickest patients at the back of the line is not the answer to issues in US healthcare. Reining in drug middlemen increasing costs for patients in need would be a far better way to improve our healthcare system. Read more:.

Read the new SFS statement on today’s @GOPHELP/@HELPCmteDems hearing on lowering healthcare costs. Lawmakers who want to support patients should oppose MFN, which would import the worst healthcare systems in the world.

New piece by @sallypipes highlights research showing that IRA price-setting is not only disincentivizing the creation of new cures but also reducing the number of more affordable generics available to patients. Read more about why Congress must address the “pill penalty,” taking.

Excellent new piece by @SallyPipes in @NEWSMAX highlights how IRA price-setting is destroying Rx development. “In the end, potentially lifesaving new uses for existing medicines may go undiscovered.”. Read more:

Instead of tying American drug prices to those in other countries where patients have access to fewer medications with longer wait times, lawmakers who want to prioritize patients should address the middlemen standing between patients and their medication. Learn more:.

Read more about why MFN pricing will hurt American patients. Not only would MFN import the worst pricing systems in the world, causing access delays and reductions in research, it won’t even work to drive prices down long term. Read more:

New research shows the IRA’s drug pricing provisions are shifting the cost burdens to patients. Increased costs = diminished access to much-needed treatments and cures. Learn more about why this law is hurting patients here: .

Despite politician claims that the passage of the disastrous IRA would help patients, research CONTINUES to show that it is hurting access to treatments. New study from @USCSchaeffer shows that most Medicare beneficiaries are actually paying more for drugs under the law.

Despite existing issues within our healthcare system, “America remains the world's undisputed superpower for biotech innovation and cures.”. Implementing MFN pricing policy and tying US drug prices to foreign nations where patients wait longer and pay more for drugs would put.

“We face a choice: Adopt Europe’s failing price controls and bureaucratic healthcare system, while watching China gain ground, or stand up for American innovation, hold our allies accountable, and protect the free-market engine that powers the next generation of medical.

The “Most Favored Nation” (MFN) policy proposal would destroy America’s innovative edge for drugs. “America is the world leader in biopharmaceuticals.” MFN would change that. Learn more:

There’s broad consensus: it’s time to rein in abusive #PBM practices. Instead of targeting the innovation that gives patients new hope, federal regulators should crack down on the real cost-drivers—#PBMs that profit while patients pay more. @TheJusticeDept @FTC.

Ask a patient what the "value" of a cure is. Any chance at getting their hands on something that could rid them of their disease and give them more time with their family is priceless. Panelists at the @TheJusticeDept @FTC are missing the real-world implications of their.

Patents fuel medical breakthroughs that give patients hope. The Hatch-Waxman Act struck a careful balance—protecting innovation while ensuring access. Undermining it with so-called “march-in” rights risks slowing the next cure. The Admin should strengthen innovation, not weaken.

The Hatch-Waxman Act unleashed a wave of medical innovation by empowering, not restricting, R&D. Today, patients benefit from over 32,000 generics—often at prices lower than in other countries. That’s real, pragmatic policy. “March-in” rights risk undoing this progress.

Since the Inflation Reduction Act passed, 51 research programs and 26 drugs have been discontinued—including efforts to find critical cures. Read why @CMSgov should pause these so-called “negotiations” in SFS’s comments to @DrOz:

Check out SFS’s comments to @USTradeRep on Most Favored Nation (MFN) drug pricing policies, which ironically don’t “favor” our “nation” at all. Read more:

SFS submitted comments to @USTradeRep outlining why Most Favored Nation (MFN) policies will abandon patients desperately awaiting new treatments and cures. Read more about why MFN is the opposite of “America First” policy here: .